Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement

@article{Esquivel2006CytoreductiveSA,
  title={Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement},
  author={J. Jes{\'u}s Esquivel and Robert P. Sticca and Paul H. Sugarbaker and Edward A. Levine and Tristan Yan and Richard B. Alexander and Dario Baratti and David L. Bartlett and Robert M. Barone and P. Barrios and Samuel C. Bieligk and Pedro Bretcha-Boix and C K Chang and Francis C. Chu and Q. Chu and Steven A. Daniel and Eelco de Bree and Marcello Deraco and Luis Manuel Dom{\'i}nguez-Parra and Dominique M Elias and R. Flynn and Jason M Foster and Alfredo Garofalo and François No{\"e}l Gilly and Olivier Glehen and Alberto G{\'o}mez-Portilla and L Gonz{\'a}lez-Bay{\'o}n and Santiago Gonz{\'a}lez-Moreno and Martin D. Goodman and Vadim Gushchin and Nader Hanna and Jens Hartmann and L. Harrison and Richard A. Hoefer and John M. Kane and Dragutin M Kecmanovic and Scott T. Kelley and Joseph A. Kuhn and Jeffrey P. Lamont and J. Lange and B. Li and Brian W. Loggie and Haile Mahteme and Gary N. Mann and R. S. Martin and R. A. Misih and Brendan John Moran and David L. Morris and Luis F. O{\~n}ate-Oca{\~n}a and Nicholas J. Petrelli and Gaulard Philippe and James F. Pingpank and A. Pitroff and Pompiliu Piso and M. Qui{\~n}ones and Lee B. Riley and Lisa A. Rutstein and Srinjoy Saha and Sadir J. Alrawi and Armando Sardi and Schlomo Schneebaum and Perry Shen and David Shibata and James E. Spellman and Alexander Stojadinovic and James Stewart and Juan Torres‐Melero and Todd M Tuttle and Victor J. Verwaal and Jos{\'e} Villar and Neal W. Wilkinson and Rami J Younan and Herbert J. Zeh and Frans A. N. Zoetmulder and Gilbert Sebbag},
  journal={Annals of Surgical Oncology},
  year={2006},
  volume={14},
  pages={128-133}
}
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin : a consensus statement 

Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis

Survival benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion was demonstrated by a prospective randomized trial for colorectal peritoneal carcinomatosis.

Hematological toxicities associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Evaluating the incidence of perioperative hematological complications and its associated risk factors in selected patients with peritoneal disease finds cytoreduction and chemoperfusion can result in systemic toxicities.

Principles and Innovations in Peritoneal Surface Malignancy Treatment

The scientific principles underscoring the rationale for CRS/HIPEC are reviewed, recent innovations and ongoing controversies are reviewed and Lack of level 1 data limits the understanding of the true benefit of CRS-HIPec.

Cytoreductive Surgery and “Hyperthermic Intraperitoneal Chemotherapy (HIPEC)”

For a long time malignant tumor manifestation of the peritoneum, peritoneal carcinomatosis (PC) was regarded as terminal. This meant that both medical and surgical palliation treatments came into

Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases

The overall survival of patients with parenchymal hepatic metastases is compared to those without and predictive factors are examined to examine predictive factors.

Factors associated with thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

We investigated the risk factors, incidence, and role of thromboprophylaxis in the development of thrombosis following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provide a promising additional treatment option for selected patients with peritoneal carcinomatosis arising from

Hyperthermic intraperitoneal chemotherapic perfusion in colorectal cancer

The term peritoneal carcinomatosis (PC) includes all tumoral dissemination, either local or massive, to the peritoneal serosa and neighbouring anatomical structures. The term PC was first used by
...

References

SHOWING 1-10 OF 11 REFERENCES

Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin

The purpose of this study was to evaluate the efficacy of intraperitoneal chemohyperthermia (IPCH) following cytoreductive surgery in patients with colorectal carcinomatosis.

Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C for Peritoneal Carcinomatosis from Nonappendiceal Colorectal Carcinoma

CS and IPHC with mitomycin C can improve outcomes for select patients with peritoneal spread from NACC, and one third of patients who undergo complete resection of gross disease have long-term survival.

Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Intraoperative Chemotherapy for Peritoneal Carcinomatosis Arising From Colon Adenocarcinoma

Considering the dismal prognosis of this condition, HIIC seems to achieve encouraging results in a selected group of patients affected with resectable peritoneal carcinomatosis arising from colon adenocarcinoma.

Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

Cytoreduction followed by HIPEC improves survival in patients with peritoneal carcinomatosis of colorectal origin, however, patients with involvement of six or more regions of the abdominal cavity, or grossly incomplete cytoreduction, had still a grave prognosis.

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

  • O. GlehenF. Kwiatkowski P. Rat
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
The therapeutic approach combining cytoreductive surgery with perioperative intraperitoneal chemotherapy achieved long-term survival in a selected group of patients with PC from colorectal origin with acceptable morbidity and mortality.

Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival.

Peritoneal carcinomatosis of colorectal origin.

Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin

Peritoneal carcinomatosis of colorectal cancer is probably best treated by cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) and from 3 years on, a consistent group of 18% of patients stayed alive.

[Indications for integrated surgical treatment of peritoneal carcinomatosis of colorectal origin: experience of the Italian Society of Locoregional Integrated Therapy in Oncology].

In conclusion PCI < or = 10, complete or optimal cytoreduction feasibility and disease-free interval have to be considered for the patients selection to the integrate treatment.